Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that the combination of gemcitabine and
doxil will have clinical activity in patients with metastatic renal cell carcinoma.